Cabometyx (cabozantinib) — United Healthcare

Initial criteria

• Diagnosis of hepatocellular carcinoma
• Used as subsequent-line systemic therapy
• One of the following: Patient has liver-confined, unresectable disease and is not a transplant candidate OR Patient has extrahepatic/metastatic disease and deemed ineligible for resection, transplant, or locoregional therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Cabometyx therapy

Approval duration

12 months